ドイハラ　ヒロヨシ   Hiroyoshi Doihara   土井原　博義    所属   川崎医科大学  医学部 臨床医学　総合外科学    職種   特任教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.
掲載誌名	正式名：Oncotarget 略　 称：Oncotarget ISSNコード：19492553/19492553
掲載区分	国外
巻・号・頁	8(16),pp.26122-26128
著者・共著者	Iwamoto Takayuki, Katagiri Toyomasa, Niikura Naoki, Miyoshi Yuichiro, Kochi Mariko, Nogami Tomohiro, Shien Tadahiko, Motoki Takayuki, Taira Naruto, Omori Masako, Tokuda Yutaka, Fujiwara Toshiyoshi, Doihara Hiroyoshi, Gyorffy Balazs, Matsuoka Junji
発行年月	2017/04
概要	BACKGROUND:The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers.RESULTS:Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P < 0.001). Post-Ki67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate signature(GSS) (66.7%: 20/30), but the difference in predictive power was not significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly downregulated after therapy (P < 0.001 and 0.041, respectively).MATERIALS AND METHODS:Core needle biopsy specimens of primary breast cancer were collected at Okayama University Hospital from hormone receptor-positive and human epidermal growth factor 2-negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from surgical samples were also collected. IHC Ki67 levels and GSS were compared between pre- and post-hormone treatment samples. Changes of gene expression pattern in short-term hormone therapy were also assessed.CONCLUSIONS:IHC based post-Ki67 levels may have distinct predictive power compared with the naïve IHC Ki67. Future studies with larger cohorts and longer follow-up periods may be needed to validate our results.
DOI	10.18632/oncotarget.15385
PMID	28412725